Cross-source evidence timeline

Metreleptin research timeline

Follow 43 selected, directly cited source records from October 30, 2013 through November 9, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

43Selected records
14Source years
3Evidence lanes
November 9, 2026Latest source date

Source year

2026

9 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02262806↗

    PeptideScanner retained ClinicalTrials.gov record NCT02262806 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05164341↗

    PeptideScanner retained ClinicalTrials.gov record NCT05164341 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  3. Literature metadata

    Metreleptin treatment of non-HIV lipodystrophy syndromes.↗

    PubMed lists PMID 34571177 in Presse medicale (Paris, France : 1983) as Journal Article, Review, with publication-date metadata of 2021-09-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT02262832↗

    PeptideScanner retained ClinicalTrials.gov record NCT02262832 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  5. Literature metadata

    Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date.↗

    PubMed lists PMID 42222073 in Frontiers in endocrinology as Case Reports, Journal Article, with publication-date metadata of 2026-05-13 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT06305182↗

    PeptideScanner retained ClinicalTrials.gov record NCT06305182 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT02325674↗

    PeptideScanner retained ClinicalTrials.gov record NCT02325674 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT06679270↗

    PeptideScanner retained ClinicalTrials.gov record NCT06679270 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  9. Literature metadata

    First metreleptin treatment for generalized lipodystrophy in Turkey.↗

    PubMed lists PMID 27717125 in Diabetes, obesity & metabolism as Case Reports, Letter, with publication-date metadata of 2016-11-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2025

6 records
  1. Clinical trials

    ClinicalTrials.gov record NCT04026178↗

    PeptideScanner retained ClinicalTrials.gov record NCT04026178 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-11-26, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  2. Literature metadata

    Metreleptin In SHORT Syndrome With Uncontrolled Diabetes.↗

    PubMed lists PMID 41080980 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-10-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2.↗

    PubMed lists PMID 40860570 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT06484868↗

    PeptideScanner retained ClinicalTrials.gov record NCT06484868 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-07-03, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT05351164↗

    PeptideScanner retained ClinicalTrials.gov record NCT05351164 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT00085982↗

    PeptideScanner retained ClinicalTrials.gov record NCT00085982 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-01-30, and PeptideScanner's reviewed identity mapping was metreleptin.↗

Source year

2024

1 record
  1. Literature metadata

    New advances in the treatment of generalized lipodystrophy: role of metreleptin.↗

    PubMed lists PMID 26396524 in Therapeutics and clinical risk management as Journal Article, Review, with publication-date metadata of 2015-09-16 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2023

1 record
  1. Literature metadata

    Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.↗

    PubMed lists PMID 25070319 in The Journal of clinical endocrinology and metabolism as Controlled Clinical Trial, Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2014-07-29 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2022

1 record
  1. Literature metadata

    Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin.↗

    PubMed lists PMID 30923630 in Clinical diabetes and endocrinology as Case Reports, Journal Article, with publication-date metadata of 2019-03-14 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2021

2 records
  1. Literature metadata

    Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report.↗

    PubMed lists PMID 33099310 in Italian journal of pediatrics as Case Reports, Journal Article, with publication-date metadata of 2020-10-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    W(h)ither metreleptin for lipodystrophy and the metabolic syndrome?↗

    PubMed lists PMID 20350904 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Editorial, Comment, with publication-date metadata of 2010 Mar-Apr (source-text precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2020

5 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02654977↗

    PeptideScanner retained ClinicalTrials.gov record NCT02654977 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-11-24, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  2. Literature metadata

    Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report.↗

    PubMed lists PMID 30745727 in Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology as Journal Article, with publication-date metadata of 2019-01-31 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes.↗

    PubMed lists PMID 31300002 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-07-12 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00657605↗

    PeptideScanner retained ClinicalTrials.gov record NCT00657605 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT00659828↗

    PeptideScanner retained ClinicalTrials.gov record NCT00659828 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin.↗

Source year

2019

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01778556↗

    PeptideScanner retained ClinicalTrials.gov record NCT01778556 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-11-13, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00461552↗

    PeptideScanner retained ClinicalTrials.gov record NCT00461552 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-05-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗

Source year

2018

1 record
  1. Literature metadata

    Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.↗

    PubMed lists PMID 26063386 in Expert opinion on biological therapy as Journal Article, Review, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2017

7 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00596934↗

    PeptideScanner retained ClinicalTrials.gov record NCT00596934 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  2. Literature metadata

    USAN Council. List No.431. New names. Metreleptin.↗

    PubMed lists PMID 11184472 in Clinical pharmacology and therapeutics as Journal Article, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Metreleptin (Myalept): a leptin analog for generalized lipodystrophy.↗

    PubMed lists PMID 25581107 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2015-01-19 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT01679197↗

    PeptideScanner retained ClinicalTrials.gov record NCT01679197 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT00140231↗

    PeptideScanner retained ClinicalTrials.gov record NCT00140231 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-07, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT00130117↗

    PeptideScanner retained ClinicalTrials.gov record NCT00130117 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-05-17, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT01155180↗

    PeptideScanner retained ClinicalTrials.gov record NCT01155180 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was metreleptin.↗

Source year

2016

3 records
  1. Regulatory

    Federal Register notice 2016-22935↗

    The Federal Register published notice 2016-22935, attributed to FDA and its parent HHS department, on 2016-09-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00025883↗

    PeptideScanner retained ClinicalTrials.gov record NCT00025883 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-08-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01511016↗

    PeptideScanner retained ClinicalTrials.gov record NCT01511016 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-01-27, and PeptideScanner's reviewed identity mapping was metreleptin.↗

Source year

2015

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00710814↗

    PeptideScanner retained ClinicalTrials.gov record NCT00710814 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-11-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00673387↗

    PeptideScanner retained ClinicalTrials.gov record NCT00673387 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00392925↗

    PeptideScanner retained ClinicalTrials.gov record NCT00392925 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was metreleptin.↗

Source year

2014

1 record
  1. Regulatory

    Drugs@FDA application BLA125390↗

    The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record's active ingredients.↗

Source year

2013

1 record
  1. Regulatory

    Federal Register notice 2013-25588↗

    The Federal Register published notice 2013-25588, attributed to FDA and its parent HHS department, on 2013-10-30. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.↗